Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4560 - PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Dimitrios Zardavas

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

D. Zardavas1, M. Regan2, R. Maibach3, B. Ruepp3, A. Hiltbrunner3, L. Blacher3, R. Gelber4, G. Gebhart5, A. di Leo6, F. Hilbers1, M. Colleoni7, G. Zoppoli8, G. Bertelli9, J. Bliss10, F. Duhoux11, M. Piccart12, L. Malorni6

Author affiliations

  • 1 Brussels, Breast International Group, 1000 - Brussels/BE
  • 2 Oncology, Dana-Farber Cancer Insititute, Boston/US
  • 3 -, International Breast Cancer Study Group, 3008 - Bern/CH
  • 4 Biostatistics, Frontier Science and Technology Research Foundation, Amherst/US
  • 5 Nuclear Medicine, Institute Jules Bordet, 1000 - Brussels/BE
  • 6 Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, 59100 - Prato/IT
  • 7 Division Of Medical Senology, European Institute of Oncology (EIO), 20141 - Milan/IT
  • 8 Oncology, University of Genova-DIMI, 16132 - Genova/IT
  • 9 Oncology, Oncology Department, Singleton Hospital, SA2 8QA - Swansea/GB
  • 10 Clinical Trials And Statistics Unit, The Institute of Cancer Research, Sutton/GB
  • 11 Oncology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 12 Medicine, Institute Jules Bordet, 1000 - Brussels/BE
More

Resources

Abstract 4560

Background

Palbociclib is an oral, potent, selective inhibitor of CDK4/6, blocking cell cycle progression from G1 into S phase. Preclinical data indicate that palbociclib has enhanced activity against luminal ER+ human breast cancer (BC) cell lines in vitro, combined with endocrine treatment. Randomized clinical trials showed significant PFS prolongation in patients with newly diagnosed and pretreated metastatic luminal BC, when palbociclib was combined with letrozole and fulvestrant respectively (PALOMA-1/2 and -3 trials). Predictive biomarkers for patient selection to receive palbociclib plus endocrine treatment are still missing.

Trial design

PYTHIA (IBCSG 53-14/BIG 14-04) is a phase II, single-arm, multicenter, study of fulvestrant and palbociclib in postmenopausal women with ER+/HER2-, advanced BC, who progressed after prior endocrine treatment (1st or 2nd line; up to 1 line of prior chemotherapy is allowed). Patients are enrolled concurrently in the AURORA program (NCT02102165), a longitudinal cohort study with extensive molecular characterization of matched primary-metastatic BC, and plasma samples. The primary endpoint is PFS, based on local assessment as per RECIST 1.1. Secondary endpoints are safety and tolerability, as well as disease control rate. Correlative objectives will assess the potential predictive value of: i) mutations and copy number aberrations in a panel of cancer-related genes, ii) gene signatures inferred by RNA sequencing, iii) early FDG-PET/CT assessment performed for a subset of 30 patients, at baseline and Day 28, and iv) a serum thymidine kinase-1 (TK1) assay, performed at baseline, Day 14 and after Cycle 1. The sample size of 120 patients was selected to have 80% power to detect a HR of 2.0 for biomarker-positive patients, with 30-50% prevalence (two-sided α = 0.05). Enrollment opened in May 2016, with the target-recruitment being 120 patients at 21 sites in Belgium, Italy and the UK.

Clinical trial identification

NCT02536742

Legal entity responsible for the study

International Breast Cancer Study Group (IBCSG)

Funding

Pfizer

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings